Mölnlycke
Investor relations
At Mölnlycke, we're driven by a passion for improving healthcare outcomes through innovation and excellence. We are transparent about our strategic objectives, financial performance, and commitment to sustainable growth. We deeply appreciate your interest and trust in Mölnlycke. Your support fuels our mission to make a meaningful impact in healthcare and deliver long-term value to our shareholders.
Mölnlycke key performance figures 2025
-
0 %organic growth
-
0EBIDTA, million EUR
-
0annual sales, million EUR
In 2025, Mölnlycke has had another strong year, achieving 2,104 MEUR in net sales while improving profitability. This corresponds to a sales growth of 4% compared to 2024. Financially, the company has improved on the strong performance of last year, with all business areas showing growth.
Furthermore, Mölnlycke continued to enhance its profitability, achieving and EBITDA of EUR 596 million with a corresponding margin of 28%.
Financial information
-
Financial reporting
-
Mölnlycke Annual report
We are transparent about our impact on environment, people and society. Each year, we report on results and performance in the integrated Annual Report.
Mölnlycke annual report 2025 covers the year ending on 31 December 2025. The report has been prepared in accordance with Global Reporting Initiative (GRI) standards. Additionally, the report has been structured to align with the Corporate Sustainability Reporting Directive (CSRD) format and requirements.
-
Investor presentations
-
Capital Markets Day
Capital Markets Day 2023 Presentation
-
Debt financing
Mölnlycke’s financial risk management is centralised to capitalise on economies of scale, synergy effects and to minimise operational risks.
The Group Treasury function is responsible for the group’s borrowing, liquidity management, currency and interest risks and acts as the internal bank for the group. In addition to ensuring that Mölnlycke has secure financing, financial transactions are conducted with the aim of limiting the Group's financial risks by, for example, diversifying the maturity profile.
Mölnlycke issues notes on the European bond market under its Euro Medium Term Note (EMTN) programme. Mölnlycke has an outstanding debt of EUR 1,800 million and USD 400 million which is long-dated and evenly distributed.
In addition to its own liquidity, Mölnlycke has a syndicated multi-currency revolving credit facility of EUR 350 million (unutilised). It was signed in 2023 as a 5+1+1 agreement. Mölnlycke has chosen to execute both the extension options in 2024 and 2025. Final maturity date is 2030. The facility is backed by a group of seven leading global and regional banks, well diversified to match Mölnlycke’s geographical footprint. The banks are BNP, Danske Bank, HSBC, ING, JP Morgan, Nordea and SEB.
Debt programmes
-
EMTN Prospectus dated 13 June 2022.pdf
Download now -
First supplement to the Base Prostectus 2022.pdf
Download now -
EMTN Prospectus dated 13 June 2023.pdf
Download now -
First supplement to the Base Prostectus 2023.pdf
Download now -
EMTN Prospectus dated 24 May 2024.pdf
Download now -
EMTN Prospectus dated 20 May 2025.pdf
Download now -
EMTN Prospectus dated 27 May 2026.pdf
Download now
-
-
Credit rating
The purpose of credit ratings is to rank the capability of a company to repay loans - short term and long term - at the time of the maturity of the loan. Mölnlycke is rated by S&P who assigned a long term rating to Mölnlycke of BBB- with a stable outlook, which was latest confirmed in August 2026.
S&P outlook dated August 2026:
The stable outlook on Mölnlycke reflects our view that the company's leading market positions in resilient segments like wound care with a large portfolio of innovative and reliable medical equipment products should enable it to sustain profitable growth. We believe the group will continue to generate FOCF and maintain a consistent financial policy which should enable it to
maintain adjusted debt to EBITDA comfortably between 3x-4x.
-
Board of Directors
Mölnlycke’s Board of Directors has the ultimate responsibility for the company and its operations.
Board of Directors -
Executive Leadership Team
Defines and implements the company’s corporate strategy and ensures day-to-day management of their operations.
Executive Leadership Team -
Our Owner
Investor AB acquired Mölnlycke in 2007. Mölnlycke is the largest wholly-owned subsidiary within Patricia Industries.
Our Owner
Latest news
-
From pressure to potential: new report reveals opportunity to increase healthcare capacity
Gothenburg, Sweden. 21 September 2026. Mölnlycke Health Care (Mölnlycke®), a global leader in MedTech, today announces the launch of The Hidden Capacity Report, a new international report revealing significant opportunities to expand day surgery and help healthcare systems improve efficiency, increase surgical throughput and enhance patient outcomes.
-
Mölnlycke to separate its surgical solutions business into a standalone company
Gothenburg, Sweden. 16 September 2026. Mölnlycke®, a global leader in MedTech, announces its intention to separate its Operating Room Solutions (ORS) and Gloves businesses into a new standalone company (referred to here as “Mölnlycke Surgical”). The separation is intended to create conditions for both Mölnlycke and Mölnlycke Surgical to reach their full potential and drive value creation long-term.
-
Major Scottish Hospital Adopts Steriwave®
UK’s Largest Hip and Knee Replacement Centre Becomes First in Scotland to Adopt Steriwave® Nasal Photodisinfection.
-
5 million and growing: scaling Granudacyn® production in Salzburg
-
First factory in China reaches key milestone and strengthens Mölnlycke’s global manufacturing network
Mölnlycke has completed construction of its first manufacturing facility in China, marking a major milestone in the company's growth journey and strengthening its ability to serve one of the world's largest and fastest growing healthcare markets.
-
Mölnlycke Health Care accelerates U.S. growth journey with three wound care product launches
Peachtree Corners, GA. 7 July, 2026. Mölnlycke Health Care (Mölnlycke®), a global leader in MedTech, has launched three product innovations in the U.S. since the start of 2026. Designed to expand access to advanced wound care solutions and strengthen the company’s U.S. presence, the portfolio expansion also supports long-term value creation across key market segments.
-
Changes to Mölnlycke Health Care Board of Directors
Gothenburg, Sweden. 23 June 2026. Mölnlycke Health Care (Mölnlycke®), a global leader in MedTech, today announces changes to its Board of Directors. Christian Cederholm will leave his Board assignment, while Filippa Stenberg will take his place as member of the Board. Thomas Kidane will step in as deputy board member.
-
Mölnlycke Health Care strengthens global manufacturing footprint to power future growth in wound care
Gothenburg, Sweden. 8 June 2026. Mölnlycke Health Care (“Mölnlycke®”), a global leader in MedTech, today confirmed a combined investment of approximately EUR 40 million in Mikkeli, Finland, and Oldham, UK. The investments strengthen the company’s global wound care manufacturing network by increasing capacity, optimising process quality and enhancing supply chain resilience and sustainability.
-
Mölnlycke Health Care and Zhende Medical form pioneering joint venture to expand access to advanced wound care solutions in China
Gothenburg, Sweden, and Shanghai, China. 21 May 2026.
Mölnlycke Health Care (“Mölnlycke®”), a global leader in MedTech and advanced wound care solutions, and Zhende Medical, a leading supplier of medical care and protection in China, today announce the formation of a new joint venture company in China to accelerate growth in one of the world’s fastest-growing wound care markets. The joint venture, majority-owned by Mölnlycke, will integrate the two companies’ wound care portfolios and commercial capabilities to offer healthcare providers, patients and the public expanded access to advanced treatments, improved care delivery and better patient outcomes across China.